DS
Daniel Skovronsky (EVP, CSO & Pres. LRL & LLY Imm) filed 2 Form 4 reports in the past 24 months (1 purchase, 1 sale), most often in Eli Lilly and Company (LLY). Across 1 priced purchase filing, the average 21-session return was +18.3% from execution and +18.3% from disclosure (delay-adjusted; derived). The largest single filing was $4.3M of LLY (5,000 sh across 3 lots, as filed), executed Feb 10 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+18.3%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+18.3%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$5.0M
shares × price, as filed
Last traded
Aug 12 2025
Filed Aug 12 2025
Median ADV $3.8B across their filed names
Open performance→Volume by month
Buys $634K
Sells $4.3M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
LLYRecent filings
LLYPURCHASE
Eli Lilly and Company
View filing →
$634K1,000 sh × $634.40
Exec Aug 12 2025
Filed Aug 12 2025 · 4:20 PM ET LLYSALE Eli Lilly and Company View filing → $4.3M
5,000 sh across 3 lots
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET